Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 December 2019 | Story Charlene Stanley | Photo Anja Aucamp
Sprouting Hope
Shadei Lepholletse, BSc Genetics and Physiology; Masabata Sebusi, BCom Accounting; and Tumelo Zondi, BCom Entrepreneurial Management; three of the directors of Sprout Africa, an agriculture and agri-processing company - the perceived potential of which has earned them each a place on the list of News24’s 100 Young Mandelas of the Future.

Enactus, 100 Young Mandelas of the Future, Sprout Africa, Masabata Sebusi, Shadei Lepholletse, Tumelo Zondi, and Farai Mzungu

Kovsie students’ innovative agri-processing venture is paying off. Two years ago, a seed of resolve was planted in four young UFS women. They entered the Enactus National Competition for entrepreneurship projects –and came stone last.

But instead of giving up, they re-grouped, re-evaluated their priorities, and came up with an innovative agri-processing community-upliftment concept that has earned each of them a place on News24’s list of 100 Young Mandelas of the Future.

“We asked ourselves what the big businesses out there were looking for when it came to community development. At that stage, we focused on arts and crafts and recycling. But we realised the need was for projects providing solutions around food insecurity, water management, and sustainable development,” explains Masabata Sebusi, final-year BCom Accounting student.

Masabata and her three partners, Shadei Lepholletse, Tumelo Zondi, and Farai Mzungu, are all studying in different fields. They pooled their diverse insights, knowledge, and perspectives. And Sprout Africa was born.

The company’s aim is to give people in rural communities training in modern farming techniques, equipping them with basic business skills and helping them to find an outlet for their produce. As part of the process, the women approached potential business partners – from local supermarkets to big commercial companies – to negotiate on behalf of the farmers.

This time, they seem to have struck the right nerve. Having won various grants while the concept as still an Enactus project, they have since registered Sprout Africa as a company. Various stakeholders have already shown interest to partner with them.

Their main advice to fellow entrepreneurs: Think outside the box, find innovative ways to solve problems, learn from the communities you serve, and collaborate with people who have different skills from you.

Except for Farai, who graduated earlier this year, all of them are in their final year of study. Next year, they won’t be job hunting like other new graduates. They’ll simply be stepping full time into their innovative enterprise.

An enterprise that promises to keep on sprouting and growing. And hopefully produce seeds of inspiration for other students to pick up.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept